LoadingLoadingLoading23 funds hold it.Insiders net selling.
Net selling: insiders sold $810K and bought $10K on the open market in 90 days (SEC Form 4). Congress: net buying of $2K to $30K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsLast report
Aug 27, 2026
Period ending
Jul 31, 2026
Earnings per share
$1.19 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 27, 2026
EPS expected
$1.13 to $1.19
Revenue expected
14 analysts
Last 30 days
Analysts cutting estimates
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jul 31, 2026 | Aug 27, 2026 | $1.24 / $1.19Yahoo Finance | +3.91% beat | $350.7M No estimate | Unavailable |
| Apr 30, 2026 | May 28, 2026 | $1.24 / $1.12Yahoo Finance | +11.18% beat | $354.6M No estimate | Unavailable |
| Jan 31, 2026 | Mar 17, 2026 | $0.95 / $0.90Yahoo Finance | +5.81% beat | $334.6M No estimate | Unavailable |
| Oct 31, 2025 | Dec 3, 2025 | $1.01 / $0.91Yahoo Finance | +10.71% beat | $322.2M No estimate | Unavailable |
| Jul 31, 2025 | Sep 2, 2025 | $1.08 / $0.92Alpha Vantage | +17.39% beat | $325.8M No estimate | Unavailable |
| Apr 30, 2025 | Jun 3, 2025 | $0.97 / $0.81Alpha Vantage | +19.75% beat | $330.8M No estimate | Unavailable |
| Jan 31, 2025 | Mar 18, 2025 | $0.69 / $0.72Alpha Vantage | -4.17% miss | $311.8M No estimate | Unavailable |
| Oct 31, 2024 | Dec 9, 2024 | $0.78 / $0.72Alpha Vantage | +8.33% beat | $300.4M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $322.2M | $334.6M | $354.6M | $350.7M |
| Cost of what it sold | $121.1M | $25.4M | $98.3M | $92.8M |
| Gross profit | $201.1M | $309.2M | $256.3M | $258.0M |
| What it spent | ||||
| Research and development | $65.9M | $70.4M | $67.8M | $73.9M |
| Sales and admin | $30.9M | $146.5M | $31.1M | $34.9M |
| Other operating costs | $24.4M | $24.9M | $54.5M | $50.5M |
| Total operating expenses | $121.2M | $241.8M | $153.4M | $159.3M |
| What was left | ||||
| Operating profit | $79.9M | $67.4M | $103.0M | $98.7M |
| Interest on debt | $14.0M | $13.3M | $12.6M | $12.6M |
| Profit before tax | $67.5M | $60.9M | $92.4M | $87.9M |
| Tax | $15.8M | $11.2M | $23.0M | $22.2M |
| Net profit | $51.7M | $49.7M | $69.4M | $65.6M |
| EBITDA | $120.4M | $100.7M | $131.5M | $142.4M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
HealthEquity Inc Estimates – GETTEX:2HE
NeutralOct 23Form 4 Healthequity Inc: Sunil Rajasekar (EVP Chief Prod & Strat Officer) For: 22 April
NeutralOct 21Barclays lifts target for HealthEquity stock to USD 115.00
BullishOct 20HealthEquity (NASDAQ:HQY) EVP Sunil Rajasekar Sells 108 Shares of Stock
Leans bullishOct 20HealthEquity EVP Sunil Rajasekar sells $13,309 in stock
Leans bullishOct 20HealthEquity EVP Sunil Rajasekar Reports Delayed Disclosure of Short Sales and Covering Trades
Leans bearishOct 20Form 4 Healthequity Inc: Sunil Rajasekar (EVP Chief Prod & Strat Officer) For: 22 April
NeutralOct 20Lobbying Update: $400,000 of HEALTHEQUITY INC. lobbying was just disclosed
NeutralOct 2032 macro signals shaping HQY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
